期刊文献+

DHX9与恶性肿瘤的治疗 被引量:1

DHX9 and treatment of malignant tumors
原文传递
导出
摘要 DHX9又称为核DNA解旋酶Ⅱ或RNA解旋酶A,属于DExH-box家族,是一种能解开RNA、DNA及异常多聚核苷酸结构的dNTP依赖性解旋酶蛋白.DHX9主要由DExH解旋酶和DExD解旋酶构成,在DNA复制、转录、翻译,RNA加工及转录,维持基因稳定性等方面具有重要的调控作用.研究表明D H X9与乳腺癌、肺癌等多种恶性肿瘤的发生密切相关,可能成为恶性肿瘤治疗的新靶点.目前在异体移植模型中已有针对DHX9的靶向药物,并有希望进行下一步临床实验.现主要就DHX9在乳腺癌、肺癌等恶性肿瘤发生、发展中的作用及治疗作一简要总结. DHX9 ,also known as nuclear DNA helicase Ⅱ or RNA Helicase A ,belongs to the DExH-box family and is an dNTP-dependent helicase protein that unwinds RNA ,DNA and abnormal polynucleotide structures .DHX9 is mainly composed of DExH helicase and DExD helicase ,and plays an important regulatory role in DNA replication ,transcription ,translation ,RNA processing and transcription ,and maintenance of gene stability .Studies have shown that DHX 9 is closely related to the occurrence of various malignant tumors such as breast cancer and lung cancer , and may become a new target for the treatment of malignant tumors .Currently ,there are targeted drugs for DHX9 in the allograft model ,and there is hope for further clinical trials .This is a brief summary of the role and treatment of DHX9 in the development and progression of malignant tumors such as breast cancer and lung cancer .
作者 马娟 赵楠楠 杨拴盈 Ma Juan;Zhao Nannan;Yang Shuanying(Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Xi' an Jiaotong University, Xi'an 710000, China)
出处 《国际呼吸杂志》 2019年第18期1407-1411,共5页 International Journal of Respiration
关键词 分子靶向治疗 DHX9 RNA解旋酶A 恶性肿瘤 Molecular targeted therapy DHX9 RNA helicase A Malignant tumor
  • 相关文献

参考文献2

二级参考文献45

  • 1王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:625
  • 2Stewart BW, Wild CP. World Cancer Report 2014 [M]. Geneva : World Health Organization, 2014 : 350-351. 被引量:1
  • 3National Research Council (US). Toward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease [M/OL]. Washington (DC): National Academies Press (US), 2011. http://www, ncbi. nlm. nih. gov/books/NBK91503. 被引量:1
  • 4Gerber DE, Oxnard GR, Govindan R. ALCHEMIST: bringing genomic discovery and targeted therapies to early-stage lung cancer[J]. Clin Pharmaeol Ther, 2015, 97 (5) : 447-450. DOI : 10. 1002/cpt. 91. 被引量:1
  • 5Steuer CE, Papadimitrakopoulou V, Herbst RS, et al. Innovative clinical trials: the LUNG-MAP study [J]. Clin Pharmacol Ther, 2015, 97 (5) : 488-491. DOI: 10. 1002/cpt. 88. 被引量:1
  • 6Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors:guideline from the College of American Pathologists, InternationalAssociation for the Study of Lung Cancer, and Association for Molecular Pathology[J]. J Mol Diagn, 2013, 15 (4) :415-453. DOI: 10. 1016/j. jmoldx. 2013.03.001. 被引量:1
  • 7Schiller JH, Gandara DR, Goss GD, et al. Non-small-cell lung cancer: then and now[J]. J Clin Oncol, 2013,31(8) : 981-983. DOI : 10. 1200/JCO. 2012.47!5772. 被引量:1
  • 8Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas[J]. Am J Surg Pathol, 2011,35 (8) : 1226-1234. DOI: 10. 1097/ PAS. 0b013e3182233e06. 被引量:1
  • 9Vari S, Pilotto S, Maugeri-Saccd M, et al. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy[J]. Expert Opin Drug Discov, 2013, 8(11) :1381-1397.DOI:10. 1517/17460441.2013.843523. 被引量:1
  • 10Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J]. N Engl J Med, 2009, 361 (10): 947-957. DOI: 10. 1056/ NEJMoa0810699. 被引量:1

共引文献988

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部